(2,3-dichlorophenyl)(3-(4-fluorophenyl)-5-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2,3-dichlorophenyl)(3-(4-fluorophenyl)-5-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone
• 英文别名: (2,3-dichlorophenyl)-[3-(4-fluorophenyl)-5-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
• 化学式: C₁₉H₁₅Cl₂FN₄O
• 分子量: 405.259
• InChiKey: HZFBDSBFUYCNMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  51
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 (2,3-dichlorophenyl)(3-(4-fluorophenyl)-5-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone
  参考文献：
  名称：

  Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists

  摘要：

  The optimization efforts that led to a novel series of methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones that are potent rat and human P2X7 antagonists are described. These efforts resulted in the discovery of compounds with good drug-like properties that are capable of high P2X7 receptor occupancy in rat following oral administration, including compounds 7n (P2X7 IC50 = 7.7 nM) and 7u (P2X7 IC50 = 7.7 nM). These compounds are expected to be useful tools for characterizing the effects of P2X7 antagonism in models of depression and epilepsy, and several of the compounds prepared are candidates for effective P2X7 PET tracers. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.004

文献信息

• P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP3191488A1

  公开（公告）日：2017-07-19
• P2X7 MODULATORS
  申请人：Jansssen Pharmaceutica NV

  公开号：US20180118749A1

  公开（公告）日：2018-05-03

  The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: These compounds are suitable for use in the treatment of diseases associated with P2X7 receptor activity such as diseases of the autoimmune and inflammatory system, diseases of the nervous and neuro-immune system, diseases involved with neuroinflammation of the Central Nervous System (CNS) or diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems.
• [EN] P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES<br/>[FR] N-ACYL-TRIAZOLOPYRAZINES MODULANT LE P2X7
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016039983A1

  公开（公告）日：2016-03-17

  The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: These compounds are suitable for use in the treatment of diseases associated with P2X7 receptor activity such as diseases of the autoimmune and inflammatory system, diseases of the nervous and neuro-immune system, diseases involved with neuroinflammation of the Central Nervous System (CNS) or diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems.